Biotech Specialty Pharma

Functional Neuromodulation

200 Front Street West
Suite 3004, P.O. Box 31, Ontario M5V 3K2 Canada
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Deep brain stimulation for Alzheimer's

Management Dan O'Connell, Co-founder, CEO, Director; Todd Langevin, President and COO; Andres Lozano, MD, PhD, Founding Scientist, Chairman of SAB, Director; Steve Targum, MD, Chief Clinical Advisor, Acting CMO; Kristen Drake, Senior Clinical Manager; Donnie Reymers, Director of DBS Therapy Development; Susan Klees, Director of Communications

Click here for Financial Data
Keywords: deep brain stimulation, Alzheimer's, cognitive disorders


Updated: Oct. 28, 2015


Functional Neuromodulation Ltd. is dedicated to advancing the application of deep brain stimulation (DBS) therapies to help improve the lives of people with Alzheimers and other memory and cognitive ......view more

Technology / Differentiation

Functional Neuromodulation applies deep brain stimulation (DBS) therapies to treat patients with Alzheimers disease (AD) as well as other memory and cognitive disorders. DBS uses an implanted medic...view more

Market / Customers

$10.2 billion market for AD in 2012. Market projected to decline to $9.5 billion by 2017, CAGR of -1.5%.2. Estimated $203 billion in direct costs of caring for AD patients in the US in 2013.......view more

Competitors / Substitutes / Alternatives

Medtronic created the DBS market, and Boston Scientific and St. Jude Medical have since entered. These companies use DBS to treat essential tremor, advanced Parkinson's disease, chronic intractable pr...view more